NKTR
Nektar Therapeutics · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +22.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +13 | 18.28M | $1.28B | +22 | −8 |
| Q1 2026 | 67 | +13 | 13.34M | $957.94M | +15 | −3 |
| Q4 2025 | 55 | +1 | 8.38M | $354.26M | +2 | n/a |
| Q3 2025 | 15 | 0 | 5.00M | $284.66M | +2 | −2 |
| Q2 2025 | 12 | -1 | 3.08M | $79.53M | +1 | −2 |
| Q1 2025 | 10 | -1 | 25.55M | $17.36M | n/a | −1 |
| Q4 2024 | 11 | 0 | 24.86M | $23.13M | n/a | n/a |
| Q3 2024 | 10 | +2 | 27.79M | $36.10M | +2 | n/a |
| Q2 2024 | 8 | n/a | 27.40M | $33.98M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 948.65K | +30.0% | $53.98M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | Morgan Stanley ✦ | 929.15K | n/a | $52.87M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (passive) | 609.11K | +46.7% | $34.66M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 4 | Millennium Management ✦ | 545.99K | -15.9% | $31.07M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 434.24K | +446.9% | $24.71M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 361.07K | New | $20.55M | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 289.05K | -3.6% | $16.45M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 278.54K | +12.7% | $15.85M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 225.24K | +70.2% | $12.82M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | State Street Global Advisors ✦ (passive) | 129.00K | +157.5% | $7.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 123.66K | New | $7.04M | 0.0% | New | 1 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 77.06K | n/a | $4.38M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Fidelity (FMR) ✦ | 39.97K | +161.6% | $2.27M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 11.98K | -32.7% | $682,000 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | JPMorgan Chase ✦ | 38 | n/a | $2,162 | 0.0% | n/c | 1 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $20.55M | 0.0% |
| Point72 Asset Management | $7.04M | 0.0% |
Exited
| AQR Capital Management | $11.06M | was 0.0% |
| Marshall Wace | $366,928 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 13.40K shares, $964 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 186 sh · $13,388
Officer, Director · 418 sh · $30,088
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology